CAMP4 Therapeutics Corp
CAMP
查看详细走势图
3.840USD
+0.250+6.96%
收盘 02/06, 16:00（美东）报价延迟15分钟
180.02M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.96%
5天
+3.78%
1月
-38.06%
6月
+168.53%
今年开始到现在
-37.36%
1年
-12.13%
查看详细走势图
TradingKey CAMP4 Therapeutics Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
CAMP4 Therapeutics Corp当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名101/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价8.75。中期看，股价处于平稳状态。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
CAMP4 Therapeutics Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
CAMP4 Therapeutics Corp亮点
亮点风险
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
业绩增长期
公司处于发展阶段，最新年度总收入652.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入652.00K美元
估值合理
公司最新PE估值-1.56，处于3年历史合理位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值1.67M
分析师目标
根据
6
位分析师
买入
评级
8.750
目标均价
+147.18%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
CAMP4 Therapeutics Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
CAMP4 Therapeutics Corp简介
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
公司代码CAMP
公司CAMP4 Therapeutics Corp
CEOMandel-Brehm (Josh)
网址https://www.camp4tx.com/
相关品种
